

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/162754/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Schröder, Mariska, Neacșu, Mihaela, Adriaansen, Bas P.H., Sweep, Fred C.G.J., Ahmed, S. Faisal, Ali, Salma R., Bachega, Tânia A.S.S, Baronio, Federico, Holtum Birkebæk, Niels, de Bruin, Christiaan, Bonfig, Walter, Bryce, Jillian, Clemente, Maria, Cools, Martine, Elsedfy, Heba, Globa, Evgenia, Guran, Tulay, Güven, Ayla, Hussein Amr, Nermine, Janus, Dominika, Lenherr Taube, Nina, Markosyan, Renata, Miranda, Mirela, Poyrazoğlu, Şükran, Rees, Aled , Salerno, Mariacarolina, Stancampiano, Marianna Rita, Vieites, Ana, de Vries, Liat, Yavas Abali, Zehra, Span, Paul N. and Claahsen-van der Grinten, Hedi L. 2023. Hormonal control during infancy and testicular adrenal rest tumor development in males with congenital adrenal hyperplasia: A retrospective multicenter cohort study. *European journal of endocrinology* 189 (4) , pp. 460-468. 10.1093/ejendo/lvad143

Publishers page: <https://doi.org/10.1093/ejendo/lvad143>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



# **Hormonal control during infancy and testicular adrenal rest tumor development in CAH males - a retrospective multi-center cohort study**

Short title: Hormonal control and TART development

*Mariska A M Schröder<sup>1,2</sup>; Mihaela Neacșu<sup>2</sup>; Bas P H Adriaansen<sup>1,2</sup>; Fred C G J Sweep<sup>2</sup>; S Faisal Ahmed<sup>3,4</sup>; Salma R Ali<sup>3,4</sup>; Tânia A S S Bachega<sup>5</sup>; Federico Baronio<sup>6</sup>; Niels Holtum Birkebæk<sup>7</sup>; Christiaan de Bruin<sup>8</sup>; Walter Bonfig<sup>9,10</sup>; Jillian Bryce<sup>4</sup>; Maria Clemente<sup>11</sup>; Martine Cools<sup>12</sup>; Heba Elsedfy<sup>13</sup>; Evgenia Globa<sup>14</sup>; Tulay Guran<sup>15</sup>; Ayla Güven<sup>16</sup>; Nermine Hussein Amr<sup>13</sup>; Dominika Janus<sup>17</sup>; Nina Lenherr Taube<sup>18</sup>; Renata Markosyan<sup>19</sup>; Mirela Miranda<sup>5</sup>; Şükran Poyrazoğlu<sup>20</sup>; Aled Rees<sup>21</sup>; Mariacarina Salerno<sup>22</sup>; Marianna Rita Stancampiano<sup>23</sup>; Ana Vieites<sup>24</sup>; Liat de Vries<sup>25</sup>; Zehra Yavas Abali<sup>15</sup>; Paul N Span<sup>26</sup>; Hedi L Claahsen-van der Grinten<sup>1</sup>*

<sup>1</sup> Department of Pediatrics, Radboud Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands; <sup>2</sup> Department of Laboratory Medicine, Radboudumc graduate school, Radboud University Medical Center, Nijmegen, The Netherlands; <sup>3</sup> Developmental Endocrinology Research Group, University of Glasgow, Glasgow, Scotland, UK; <sup>4</sup> Office of Rare Conditions, University of Glasgow, Glasgow, Scotland, UK; <sup>5</sup> Laboratory of Hormones and Molecular Genetics-LIM 42, Department of Endocrinology and Metabolism, University of Sao Paulo, Sao Paulo, Brazil; <sup>6</sup> Dpt Hospital of Woman and Child, Pediatric Unit, IRCCS AOU di Bologna, Policlinico di S.Orsola, Bologna, Italy; <sup>7</sup> Aarhus University Hospital, Department of Pediatrics and Steno Diabetes Center Aarhus, Aarhus, Denmark; <sup>8</sup> Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands; <sup>9</sup> Department of Pediatrics, Technical University Munich, Munich, Germany; <sup>10</sup> Department of Pediatrics, Klinikum Wels-Grieskirchen, Wels, Austria; <sup>11</sup> Pediatric Endocrinology Unit, Hospital Vall d'Hebron, Autonomous University of Barcelona, CIBERER, Barcelona, Spain; <sup>12</sup> Pediatric Endocrinology, Internal Medicine and Pediatric Research Unit, University Hospital Ghent, Ghent University, Ghent, Belgium; <sup>13</sup> Pediatrics Department, Ain Shams University, Cairo, Egypt; <sup>14</sup> Ukrainian Research Center of Endocrine Surgery, Endocrine Organs and Tissue Transplantation, MOH of Ukraine, Kyiv, Ukraine; <sup>15</sup> Pediatric Endocrinology and Diabetes, Marmara University, Istanbul, Turkey; <sup>16</sup> Baskent University Medical Faculty, Istanbul Hospital; Pediatrics Department, Ain Shams University, Cairo, Egypt; <sup>17</sup> Department of Pediatric and Adolescent Endocrinology, Institute of Pediatrics, Jagiellonian University Medical College, and Children's University Hospital, Krakow, Poland; <sup>18</sup> Department of Pediatrics, Division of Endocrinology, University Children's Hospital Zurich, Zurich,

University of Zurich, Switzerland; <sup>19</sup> Yerevan State Medical University, Yerevan, Armenia; <sup>20</sup> Istanbul University, Istanbul Faculty of Medicine, Unit of Pediatric Endocrinology, Istanbul, Turkey; <sup>21</sup> Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK; <sup>22</sup> Pediatric Endocrine Unit, Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy; <sup>23</sup> Department of Pediatrics, Endocrine Unit, IRCCS San Raffaele Scientific Institute, Endo-ERN Center for Rare Endocrine Conditions, Milan, Italy; <sup>24</sup> Centro de Investigaciones Endocrinológicas Buenos Aires, Buenos Aires, Argentina; <sup>25</sup> The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel and Felsenstein Medical Research Center at Petach Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; <sup>26</sup> Radiotherapy & Oncolmmunology Laboratory, Department of Radiation Oncology, Radboudumc graduate school, Radboud University Medical Center, Nijmegen, The Netherlands;

**Corresponding author:** Hedi L. Claahsen – van der Grinten; [hedi.claahsen@radboudumc.nl](mailto:hedi.claahsen@radboudumc.nl)

**Word count:** 4094

## Abstract (240/250)

**Background:** Testicular adrenal rest tumors (TART), often found in male patients with congenital adrenal hyperplasia (CAH), are benign lesions causing testicular damage and infertility. We hypothesize that chronically elevated adrenocorticotrophic hormone (ACTH) exposure during early life may promote TART development.

**Objective:** This study aimed to examine the association between commencing adequate glucocorticoid treatment early after birth and TART development.

**Methods:** This retrospective multicenter (n=22) open cohort study collected longitudinal clinical and biochemical data of the first 4 years of life using the I-CAH registry and included 188 male patients (median age 13 years; IQR: 10-17) with 21-hydroxylase deficiency (n=181) or 11-hydroxylase deficiency (n=7). All patients underwent at least one testicular ultrasound.

**Results:** TART were detected in 72 (38%) of the patients. Prevalence varied between centers. When adjusted for CAH phenotype, a delayed CAH diagnosis of more than 1 year, compared to a diagnosis within 1 month of life, was associated with a 2.6 times higher risk of TART diagnosis. TART onset was not predicted by biochemical disease control or bone age advancement in the first four years of life, but increased height SDS at the end of the four-year study period was associated with a 27% higher risk of TART diagnosis.

**Conclusion:** A delayed CAH diagnosis of more than 1 year versus CAH diagnosis within one month after birth was associated with a higher risk of TART development, which may be attributed to poor disease control in early life.

## 60 Significance statement

61 Testicular adrenal rest tumors (TART) are common in males with congenital adrenal hyperplasia (CAH) and are  
62 an important cause of gonadal dysfunction. Chronically elevated ACTH levels in poorly treated patients are  
63 considered the main factor in TART development. However, previous studies on long-term CAH control and TART  
64 development are equivocal, and it remains unclear why TART occur less commonly in patients with acquired  
65 conditions with chronically elevated ACTH levels. This retrospective study describes the largest cohort of CAH  
66 males being evaluated for TART so far and shows that a delayed CAH diagnosis may be associated with a higher  
67 risk of TART. This may be attributed to lack of ACTH suppression during early life and may strengthen the case  
68 for implementation of neonatal screening and early effective management of male newborns with CAH.

## 69 Introduction

70 Congenital adrenal hyperplasia (CAH) are a group of autosomal recessive disorders affecting adrenal  
71 steroidogenesis. CAH can be caused by mutations in several genes, including the most commonly affected  
72 *CYP21A2* or *CYP11B1* gene, resulting in 21-hydroxylase deficiency (21OHD) and 11 $\beta$ -hydroxylase deficiency  
73 (11OHD), respectively [1, 2]. Based on residual 21-hydroxylase activity, 21OHD is commonly classified into three  
74 subtypes; salt-wasting (0-1% residual activity), simple virilizing (1-5% residual activity), and non-classic 21OHD  
75 (20-50% residual activity) [1]. For both 21OHD and 11OHD, low levels of glucocorticoids lead to an overactivated  
76 hypothalamic-pituitary-adrenal axis with chronic hypersecretion of adrenocorticotrophic hormone (ACTH).  
77 Elevated blood ACTH levels overstimulate the adrenal cortex with increased production of precursor steroids  
78 upstream of the enzymatic defect and higher levels of adrenal androgens. Glucocorticoid treatment aims to  
79 substitute the low glucocorticoid levels and to inhibit the hypersecretion of ACTH and adrenal androgens [3].

80 Testicular adrenal rest tumors (TART) are a common complication in males with CAH, with a reported prevalence  
81 varying between 14 and 86%, depending on the age, method of detection and type of CAH [4]. These benign  
82 tumors are typically located within the rete testis and may cause testicular damage [5] and infertility [6, 7]. The  
83 etiology of TART is still not fully understood. Chronically elevated ACTH levels are considered important for TART  
84 development [8] and growth, as TART express the ACTH receptor MC2R [9] and respond to ACTH by means of  
85 elevated steroid hormone production *in vitro* [10]. Multiple studies have linked the presence of TART to poor  
86 disease control [4], but a clear relationship between TART development and elevated ACTH levels is not  
87 established and an association between longer-term poor disease control and TART development is not  
88 consistently observed [11, 12]. It could be speculated that ACTH exposure during infancy and childhood, or even  
89 during pregnancy, is a prerequisite for the development of TART. Neonatal exposure to high ACTH levels may  
90 prevent (complete) regression of adrenal rest tissue [13] or a yet undefined cell population. We, therefore,  
91 hypothesize that high ACTH exposure during early life is promoting the development of TART during the patient's  
92 lifetime. This theory is supported by the clinical observation that TART are uncommon in acquired conditions  
93 with elevated ACTH levels in later life [14]. This study aims to investigate the association between hormonal  
94 control during infancy and early childhood and TART development during lifetime in a large cohort of males with  
95 CAH due to 21OHD or 11OHD. In addition, we aim to verify if an early start of treatment after birth lowers the  
96 risk of TART development.

## 97    **Methods**

### 98    *Data collection*

99    In this retrospective open cohort study, pseudonymized data from the I-CAH registry -an international database  
100    on CAH patients with data collected as part of routine clinical care [15]- was analyzed. This registry is approved  
101    by the National Research Ethics Service (19/WS/0131) and deposition of patient information into the registry  
102    was preceded by informed consent from patients and/or guardians. The study complies with the Declaration of  
103    Helsinki. Retrospective data was collected from individuals with 46,XY karyotype, genetically and/or  
104    biochemically confirmed CAH diagnosis due to 21OHD or 11OHD, and at least one testicular ultrasound for TART  
105    evaluation. Additional data was collected and pseudonymized by the attending physician. Retrospective data on  
106    height, biochemical disease control, treatment, and bone age, were collected during five visits in the first four  
107    years of life: at diagnosis and four consecutive annual visits. Retrospective data collected after 4.5 years of age  
108    (with the exception of data on TART development) were not included. Contemporary data (also obtained after  
109    4.5 years of age) regarding TART development were collected. In case of missing data, centers were actively  
110    approached to add missing information.

### 111    *Data interpretation*

112    Biochemical disease control was evaluated using interpreted laboratory results for androstenedione and/or 17-  
113    hydroxyprogesterone (undertreatment / adequate / overtreatment).. Androstenedione concentrations were  
114    predominantly (91% of reported sample type) measured in serum, and were occasionally reported to be  
115    measured in urine (5%), plasma (3%), or saliva (1%). The steroid 17-hydroxyprogesterone was predominantly  
116    measured in serum (96%), and occasionally reported to be measured in plasma (5%), or saliva (1%). Adequacy of  
117    treatment was monitored according to international guidelines [16], through measurement of androstenedione  
118    and 17-hydroxyprogesterone. Because of differences in sample type, time of measurement with respect to  
119    treatment, and center-specific reference values, hormone levels were interpreted by the attending physician or  
120    study lead using center's in-house reference values. For one center, including 7 patients, testosterone levels were  
121    used to assess biochemical disease control. ACTH levels quantified either in plasma or serum, together with their  
122    interpretation (low/normal/high) were collected.

As measures for past long-term hormonal control, data on bone age advancement and height velocity by calculating height for age standard deviation scores (SDS) were assessed for every visit. Bone age advancement was calculated by subtracting the chronological age from the measured bone age, mainly assessed by a pediatric endocrinologists using the Greulich and Pyle method. Height-for-age SDS corrected for target height SDS was calculated for every visit, using international height-for-age references of the World Health Organization [17]; For this, height SDS was calculated using patient's height for age at assessment and the international mean height for age and standard deviation from the WHO. The height SDS was subtracted by the target height SDS, which was calculated using the formula described by Hermanussen and Cole [18], using paternal and maternal final height, and male and female references of the WHO at age nineteen.

Patients with 21OHD were, based on genotypes, classified into presumed phenotypes (salt-wasting (SW), simple-virilizing (SV), non-classic (NC), not known)[19-26]. Patients with 11OHD were classified as "not known" phenotype for analyses. Adrenal crisis at diagnosis was specified as either a recorded salt-wasting crisis or Addisonian crisis at diagnosis.

### *Statistical analysis*

Data analyses were performed in R [27]. Descriptive statistics are presented as ratios with percentages or median with interquartile range (IQR). Mann Whitney U tests were used to compare differences in continuous data between patients with or without TART and chi-square tests were used to test relations between categorical variables, when there was no need for normalization for other parameters. The approximate age at diagnosis and start of treatment were obtained or calculated from dates and consequently categorized into groups of <1 month, > 1 month but < 1 year, and > 1 year. Because of the right-censored nature of the data, Cox proportional hazard analyses were performed using the R survival package [28], providing hazard ratios (HR) with 95% confidence intervals. Survival plots were obtained using the R Survminer package [29]. For categorical variables, missing data was incorporated in the analyses as 'not known', to evaluate if missing data was informative. If data availability allowed it, the effect of predictors on risk of TART diagnosis was adjusted for the presumed CAH phenotype. The assumption of proportional hazards was tested using Schoenfeld's test. P-values smaller than 0.05 were considered statistically significant.



## Results

### *Description of patient cohort*

In total, 188 male patients diagnosed with CAH due to 21OHD (n=181) or 11OHD (n=7) were included from 22 centers in 17 countries (Table 1). All patients had at least one testicular ultrasound, and 141 (75%) were screened regularly for TART by testicular ultrasound. The median age at most recent testicular ultrasound was 13 years (IQR: 10-17, Table 1). TART were detected in 38.3% (72/188) of the patients. The number of patients included per center ranged from one to 27 and the prevalence of TART ranged from 0% to 100%. Sixty-two participants had bilateral TART and ten had unilateral TART. The youngest patient in which TART were detected was just 2 years old (upon 11OHD diagnosis) and half of the patients (IQR) with detected TART were between 10.8 and 18.3 years old. The median TART size at detection was 9 mm (IQR: 4.8 – 15.0), with one additional patient having a "point-like" tumor. TART were surgically removed in seven patients from five centers. For eleven patients with TART (15%), TART-related complaints were documented, being (testicular) pain (n=6), gonadal dysfunction (n=2), (hypergonadotropic) hypogonadism (n=6), and azoospermia (n=3). Based on the genetic information, most patients with 21OHD were classified as SW (57%), followed by SV (16%), and NC CAH (8%). Five patients (3%) had a heterozygous or homozygous P30L mutation, which is known to cause a phenotype in between SV and NC [24], and were therefore classified as SV/NC. Another patient with a P453S and I2G mutation was also classified as SV/NC [30]. For 29 (16%) patients with 21OHD, genetic information was either not available (n=23) or could not be classified into presumed phenotypes (n=6). SW phenotype was associated with a 3.3 (1.2-9.1) times higher risk of TART diagnosis compared to the SV phenotype (Figure 1A; Table 2). Remarkably, the SV/NC patients had a significantly higher risk of TART diagnosis than SV patients. The low number of patients with this subtype (n=6) rendered a wide 95% confidence interval (1.9-38.5). TART were diagnosed in two of fourteen patients (14%) with presumed NC CAH (Table 1), who both had homozygous V281L mutations.

### *Age at diagnosis and TART development*

Diagnosed children were predominantly treated with hydrocortisone, but also prednisolone or "other" glucocorticoids were occasionally prescribed during the first four years of life. Of the treated patients with available data, the median hydrocortisone(-equivalent)[31] doses during the first four years of life were 5.5 mg (IQR = 5.0-7.5), 7.5 mg (5.0-10), 7.5 mg (6.9-10), and 9.0 mg (7.5-12), around each birthday respectively.

177 Normalized for body surface area (calculated with formula of Mosteller [32]), this corresponded to 27.9 mg/d/m<sup>2</sup>  
 178 (22.9-37.9), 20.7 mg/d/m<sup>2</sup> (16.8-29.4), 19.7 mg/d/m<sup>2</sup> (16.5-24.7), and 17.2 mg/d/m<sup>2</sup> (15.1-20.8), respectively.  
 179 To investigate if poor disease control with concomitant high ACTH exposure in early life affected risk of TART  
 180 diagnosis, we first evaluated whether a delayed diagnosis -and therefore a longer untreated period- increased  
 181 the risk of TART diagnosis during lifetime. Unadjusted, a delayed CAH diagnosis of more than one year, compared  
 182 to a diagnosis within 1 month, did not significantly affect TART development (HR=1.8; p=0.06). However, as  
 183 patients with SW 21OHD (which have a 3.3-times higher risk of TART development) are typically diagnosed earlier  
 184 than SV or NC 21OHD patients (data not shown), the association between age at diagnosis and TART  
 185 development is underestimated if left unadjusted for the negative confounding effect of CAH phenotype. When  
 186 adjusted for CAH phenotype, a delayed CAH diagnosis (or presentation) of more than one year, compared to a  
 187 diagnosis within 1 month, was associated with 2.6 times higher risk of TART diagnosis (Table 2). A slightly delayed  
 188 CAH diagnosis between one month and one year of age was not significantly associated with a higher risk of TART  
 189 diagnosis. When solely focusing on patients with SW 21OHD (n=98; events = 35), a significant impact of age at  
 190 diagnosis on TART development was observed; Patients with a delayed diagnosis of more than 1 year faced a  
 191 3.4-fold increase in risk of TART development (p<0.01) compared to patients diagnosed within the first month.  
 192 Figure 1B illustrates the non-occurrence of TART over time in patients with salt-wasting CAH, stratified for age at  
 193 diagnosis. A diagnosis of CAH within the first month of life did not prevent TART development in all patients, but  
 194 seemed to overall delay the presence of TART. No effect of age at diagnosis on TART development was observed  
 195 when separately analyzing the patients with SV 21OHD (HR=0.7; p = 0.8), potentially because of the small sample  
 196 size (n=27, events=4).  
 197 Neonatal screening was performed in at least 32% of the patients with 21OHD and resulted as expected in earlier  
 198 21OHD diagnosis (Figure 1C; Chi-square test; p <0.001); Sixty-eight of the 102 patients (67%) without neonatal  
 199 screening for 21OHD were diagnosed after the first month of life, of which 35 patients (34%) were diagnosed  
 200 after one year of age, while only four patients neonatally screened for 21OHD (7%) were diagnosed after the first  
 201 month of life. Of these four patients, three patients had a false negative result, and one patient was diagnosed  
 202 just after one month because of delayed result. Adjusted for CAH phenotype, patients diagnosed by a neonatal  
 203 screening program faced a 3.2 times lower risk of TART development compared to CAH patients not diagnosed  
 204 by a neonatal screening program (p<0.01). Neonatal screening was also associated with lower occurrence (17%

versus 58%) of adrenal/salt-wasting crisis at diagnosis in patients with 21OHD (Figure 1B; Chi square test;  $p<0.001$ ). Two of four patients prenatally treated with dexamethasone developed TART. The exact timeframe of dexamethasone treatment is not known.

#### *Biochemical disease control and TART development*

ACTH is not routinely measured in clinical practice and retrospective data on ACTH levels were available only for a total of 145 assessments (120 with interpretation) of 69 patients (52 with interpretation). Patients that were categorized as undertreated had significantly higher blood ACTH levels in contrast to patients classified as adequately treated or overtreated, when all assessments were combined (Pairwise Mann-Whitney U tests with Benjamini-Hochberg adjustment). Of the 52 ACTH assessments that were classified as “high”, 20 patients were classified as undertreated, while 26 patients were classified as adequately treated, and six patients were even classified as overtreated.

Data on interpreted biochemical disease control (undertreatment, adequate treatment, or overtreatment) were available for 44 patients at a visit between 0.5 and 1.5 year of age, for 52 patients at a visit between 1.5 and 2.5 year of age, 47 patients at a visit between 2.5 and 3.5 year of age, and 54 patients at a visit between 3.5 and 4.5 year of age. Of the 59 patients with multiple (available) biochemical assessments during their first four years of life, 40 patients had variable biochemical assessments over the years. Undertreatment versus adequate or overtreatment at yearly visits of the first four years of life did not predict TART diagnosis later in life (Table 2).

#### *Growth acceleration, bone age advancement, and TART development*

To evaluate if chronic poor disease control during early life was associated with TART development, also the relation between growth acceleration or bone age advancement and TART development was assessed. Exposure to high androgen levels leads to growth acceleration and bone age advancement and patients with high androgen levels presumably also have high ACTH levels. Data on patient’s height and their biological mother’s and father’s final height was available for 51 patients with an assessment within the first 6 months of life (age 0) and for 81, 90, 96, and 98 patients around their 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup> and 4<sup>th</sup> birthday, respectively (Figure 2A). Corrected height SDS at the first four height assessments did not differ between patients that developed or did not (yet) develop TART (Figure 2A). However, at the last assessment, around the 4<sup>th</sup> birthday, the median (IQR) height SDS was significantly higher (Wilcoxon signed rank test;  $p=0.02$ ) in patients with TART (0.49 SDS (-0.5 – 1.9)) versus

without TART (-0.1 SDS (-0.8 – 0.7)) (Figure 2). Cox proportional hazard analysis showed that patients with an increased corrected height SDS of 1 SDS around the fourth birthday had a 27% higher risk of a positive TART screening (Table 2). Data on bone age was available for 15, 33, 48, and 58 patients around the 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup>, and 4<sup>th</sup> birthday, respectively. No statistically significant difference in bone age versus chronological age during yearly visits of the first four years of life between patients that developed TART versus patients that did not develop TART were observed (Figure 2B). Bone age advancement during the first four years of life did not predict TART detection (Table 2).

## Discussion

This retrospective open cohort study describes the largest cohort of CAH males being evaluated for TART. Using the I-CAH registry, this study was able to include a total of 188 patients. This study investigated the association between biochemical disease control during infancy and early childhood and the development of TART in male patients with 21OHD or 11OHD. It was hypothesized that high ACTH exposure during early life is promoting the development of TART. Postnatal trophic stimulation of adrenal(-like) tissue by ACTH may prevent physiological reduction of the relatively large-sized neonatal adrenal gland [33, 34], as well as regression of adrenal rest tissue [13] or a yet undefined cell-population in the testes. Neonatal trophic stimulation of cells within the testes may even increase the pool of ACTH-sensitive cells that could grow into significantly sized TART during periods of poor hormonal control. When adjusted for CAH phenotype, a delayed CAH diagnosis of more than one year after birth was associated with a higher risk of TART development. This relation might be attributed to chronically ACTH exposure of cells within the infantile testes. Neonatal screening for CAH resulted in earlier diagnosis and may therefore help improving early CAH treatment and lower the risk of TART development. Previously, a large epidemiological study by Falhammar et al. [35] reported that fertility outcomes (number of men that fathered a child) normalized for men with CAH after the introduction of neonatal screening. Although a potential role of TART could not be established in this study, this study could possibly complement our results. It should be noted that early CAH diagnosis and consequent start of treatment within the first month of life did not prevent TART development in all patients. TART have also been described in patients with acquired conditions with elevated ACTH-hypersecretion [36-40], suggesting that neonatal (or prenatal) ACTH overexposure is not a prerequisite for

TART development. However, TART occurrence is rare in acquired endocrinopathies [14], despite high ACTH exposure during adulthood. Therefore, it could be speculated that chronic ACTH exposure during infancy in patients with CAH may promote and accelerate TART development by preventing or inhibiting regression of adrenal rest cells or a yet undefined cell population and by facilitating expansion of these cells that could develop into detectable TART earlier on, within a shorter period of poor disease control.

A potential confounder of our study should, however, be discussed. Although the number of patients per center was low and prevalence per center could not be properly estimated, difference in prevalence of TART between centers has been reported previously [4] and there might be a center-effect on the risk of TART development. For centers with less experience in CAH care or a lower quality health-system in general, patients might be at higher risk for delayed CAH diagnosis (less CAH awareness and/or no neonatal screening) and for (earlier) TART development. Difference in TART prevalence between centers advocates for improvement and uniformity of CAH care and guidelines to prevent this long-term complication. The number of patients per center did not allow normalization for center-specific effects, nor did it allow for sub-analyses per center. Previous smaller studies have not found differences in age at diagnosis or treatment onset between patients with or without TART [41-43]. However, two [41, 42] of the three studies did not specifically evaluate this relation. Even more importantly, in contrast to the previous studies, the current study adjusted for disease severity (which is essential as age at CAH diagnosis varies with disease severity [43] and interferes with risk of TART development) and for the right-censored nature of the data. Of note, patients with SW 21OHD are generally diagnosed and treated earlier than patients with SV 21OHD (data not shown). Still, patients with SW phenotype faced a 3-fold higher risk of TART development in comparison to patients with the SV phenotype. Similar results were reported by Reisch et al. [12]. This observation probably stresses that the effect of CAH disease severity is larger than the effect of a delayed CAH diagnosis on the risk of TART development. Moreover, the absence of a detected association between a delayed CAH diagnosis between 1 month and 1 year, compared to a CAH diagnosis within the first month of life, and the development of TART might indicate that a considerable delay in CAH diagnosis is needed in order to observe an impact on TART development. In this cohort, TART were detected in two genetically proved NC patients. Although not commonly reported [44], TART have previously been described in NC CAH [45-47].

Besides neonatal ACTH exposure, fetal or embryological ACTH exposure or faulty mechanisms occurring during fetal development have been proposed of being key in TART development [12, 48], and may also explain the

predisposition to TART development in patients with CAH versus patients with later-onset ACTH hypersecretion; Turcu *et al.* [48] noticed that ‘adrenal remnants’ were more prevalently observed in neonates and infants with 21OHD [49] versus unaffected neonates [50]. Although the exact timeframe of prenatal dexamethasone treatment was unknown and the number of patients is limited, the current study showed that prenatal dexamethasone treatment did not prevent TART development, as two of four prenatally treated patients still developed TART.

Previous studies have been aiming to relate TART (development) to measures of hormonal control, measured either at the moment of TART detection or in a certain period prior to TART detection [8, 12, 41-43, 45, 48, 51-57]. ACTH is not commonly measured as part of clinical care and multiple retrospective studies, including this study, used other measures of disease control, assuming that these parameters reflect ACTH levels. In previous studies, TART have been reported in obviously “well-controlled” patients [51, 56, 57]. Data on ACTH levels in these patients were not available or reported. The goal of conventional glucocorticoid therapy in CAH is to suppress the adrenal androgen concentrations, but not 17OHP levels (and likely ACTH levels) in order to prevent glucocorticoid overtreatment [16]. Novel therapies allowing more efficient suppression of ACTH without the need of supraphysiological glucocorticoids doses, such as the use of CRH antagonists or ACTH receptor antagonists, are therefore promising strategies to lower the prevalence of TART [3]. The current study showed that ACTH levels could indeed still be elevated in patients classified as adequately treated or even overtreated. The use of other steroid hormones to define disease control as an estimate of ACTH exposure is therefore an important limitation. This study also collected data on ACTH levels during early childhood, but no sufficient data was available to study associations with TART development. The sometimes elevated ACTH levels in adequately or overtreated patients, but also the degree of missing data on biochemical disease control may explain why we -but also other studies- did not find an association between biochemical disease control (during the first four years of life) and TART detection. In addition, yearly biochemical assessments are only a snapshot of disease control during that year. Therefore, this study also assessed growth velocity and bone age advancement, as a result of chronic androgen overexposure and, likely, ACTH overexposure. At the end of the four-year study-period, an increased height for age SDS, reflecting poor past disease control [58], was associated with higher risk of TART development. Difference between chronological age and bone age seemed higher for patients that developed TART at the end of the study period, but advanced bone age at the end of the follow-up period did

not significantly predict TART diagnosis. The discrepancy between bone age advancement and increased height for age SDS can probably be explained by the lower number of patients with available bone age data. Increased growth velocity or advanced bone maturation may not yet be expected to be substantial in poorly treated patients with CAH during the first three years of life, at least not during the first year of life in untreated SV patients [59]. Nonetheless, together the data suggests that poor disease control during the first four years of life is associated with increased risk of TART development, already in childhood. Clinicians should be vigilant for TART already in early childhood. Although we were interested in the relation between ACTH exposure during early childhood and TART diagnosis later in life, it would be of interest to also review data after four years of life, in order to verify if poor disease control during early life reflects poor disease control after this four-year period, affecting TART development. While the size of this international patient cohort is a strength, potential variation between centers with respect to patient care or experience in testicular ultrasonography could be a limitation. A prospective multicenter study with harmonized evaluation of hormonal disease control and treatment compliance at set timepoints along with standardized evaluation of TART is of interest to verify our findings. Nonetheless, this international study gives a clear image on the prevalence of TART and their medical impact on males with CAH and the potential impact of delayed diagnosis and poor disease control on TART development.

In conclusion, adjusted for CAH phenotype, a delayed CAH diagnosis was associated with a higher risk of TART development, which might be due to longer and higher neonatal ACTH exposure, but may also reflect the differences in TART risk across centers.

**Acknowledgements:** We would like to thank Dr. A.E. van Herwaarden for critically reading the manuscript.

**Declaration of interest:** SFA has received an unrestricted education grant from Neurocrine Biosciences and acted as a consultant to Novo Nordisk. AR is involved in clinical trials in CAH sponsored by Diurnal Ltd and Neurocrine Biosciences. HLC is involved in clinical trials in CAH sponsored by Spruce Biosciences. All other authors declared to have no conflict of interest.

**Funding:** This project has received support from the I-CAH Registry project that currently receives an unrestricted education grant from Neurocrine Biosciences. The initial development of the Registry was supported by the Medical Research Council (G1100236), the Seventh European Union Framework Program (201444) and the European Society for Paediatric Endocrinology Research Unit.

## 342 References

- 343 1. Claahsen-van der Grinten, H.L., et al., *Congenital Adrenal Hyperplasia-Current Insights in*  
344 *Pathophysiology, Diagnostics, and Management*. Endocr Rev, 2022. **43**(1): p. 91-159.
- 345 2. Auchus, R.J., *The uncommon forms of congenital adrenal hyperplasia*. Curr Opin Endocrinol  
346 Diabetes Obes, 2022. **29**(3): p. 263-270.
- 347 3. Schroder, M.A.M. and H.L. Claahsen-van der Grinten, *Novel treatments for congenital*  
348 *adrenal hyperplasia*. Rev Endocr Metab Disord, 2022. **23**(3): p. 631-645.
- 349 4. Engels, M., et al., *Testicular Adrenal Rest Tumors: Current Insights on Prevalence,*  
350 *Characteristics, Origin, and Treatment*. Endocr Rev, 2019. **40**(4): p. 973-987.
- 351 5. Claahsen-van der Grinten, H.L., et al., *Testicular adrenal rest tumors in patients with*  
352 *congenital adrenal hyperplasia can cause severe testicular damage*. Fertil Steril, 2008. **89**(3):  
353 p. 597-601.
- 354 6. Jha, S., et al., *Individualizing Management of Infertility in Classic Congenital Adrenal*  
355 *Hyperplasia and Testicular Adrenal Rest Tumors*. J Endocr Soc, 2019. **3**(12): p. 2290-2294.
- 356 7. Tanaka, M., et al., *Two cases of reversible male infertility due to congenital adrenal*  
357 *hyperplasia combined with testicular adrenal rest tumor*. Reprod Med Biol, 2018. **17**(1): p.  
358 93-97.
- 359 8. Mazzilli, R., et al., *The High Prevalence of Testicular Adrenal Rest Tumors in Adult Men With*  
360 *Congenital Adrenal Hyperplasia Is Correlated With ACTH Levels*. Front Endocrinol (Lausanne),  
361 2019. **10**: p. 335.
- 362 9. Lottrup, G., et al., *Abundance of DLK1, differential expression of CYP11B1, CYP21A2 and*  
363 *MC2R, and lack of INSL3 distinguish testicular adrenal rest tumours from Leydig cell tumours*.  
364 Eur J Endocrinol, 2015. **172**(4): p. 491-9.
- 365 10. Turcu, A.F., et al., *Profiles of 21-Carbon Steroids in 21-hydroxylase Deficiency*. J Clin  
366 Endocrinol Metab, 2015. **100**(6): p. 2283-90.
- 367 11. Rohayem, J., et al., *Semen quality and testicular adrenal rest tumour development in 46,XY*  
368 *congenital adrenal hyperplasia: the importance of optimal hormonal replacement*. Eur J  
369 Endocrinol, 2021. **184**(4): p. 487-501.
- 370 12. Reisch, N., et al., *Testicular adrenal rest tumors develop independently of long-term disease*  
371 *control: a longitudinal analysis of 50 adult men with congenital adrenal hyperplasia due to*  
372 *classic 21-hydroxylase deficiency*. J Clin Endocrinol Metab, 2013. **98**(11): p. E1820-6.
- 373 13. Falco, E.C., et al., *Adrenal Rests in the Uro-genital Tract of an Adult Population*. Endocr  
374 Pathol, 2021. **32**(3): p. 375-384.
- 375 14. Verhees, M.J.M., et al., *Re: Testicular Adrenal Rest Tumors in Boys and Young Adults with*  
376 *Congenital Adrenal Hyperplasia: M. S. Kim, F. Goodarzian, M. F. Keenan, M. E. Geffner, C. M.*  
377 *Koppin, R. E. De Filippo and P. J. Kokorowski J Urol 2017;197:931-936. J Urol, 2018. 199*(5): p.  
378 1357-1358.
- 379 15. Ali, S.R., et al., *The Role of International Databases in Understanding the Aetiology and*  
380 *Consequences of Differences/Disorders of Sex Development*. Int J Mol Sci, 2019. **20**(18).
- 381 16. Speiser, P.W., et al., *Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase*  
382 *Deficiency: An Endocrine Society Clinical Practice Guideline*. J Clin Endocrinol Metab, 2018.  
383 **103**(11): p. 4043-4088.
- 384 17. Organization, W.H. *Length/height-for-age*. Available from: [https://www.who.int/tools/child-](https://www.who.int/tools/child-growth-standards/standards/length-height-for-age)  
385 [growth-standards/standards/length-height-for-age](https://www.who.int/tools/child-growth-standards/standards/length-height-for-age).
- 386 18. Hermanussen, M. and J. Cole, *The calculation of target height reconsidered*. Horm Res, 2003.  
387 **59**(4): p. 180-3.
- 388 19. New, M.I., et al., *Genotype-phenotype correlation in 1,507 families with congenital adrenal*  
389 *hyperplasia owing to 21-hydroxylase deficiency*. Proc Natl Acad Sci U S A, 2013. **110**(7): p.  
390 2611-6.



20. Concolino, P., et al., *Molecular diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: an update of new CYP21A2 mutations*. Clinical Chemistry and Laboratory Medicine, 2010. **48**(8): p. 1057-1062.
21. Simonetti, L., et al., *CYP21A2 mutation update: Comprehensive analysis of databases and published genetic variants*. Hum Mutat, 2018. **39**(1): p. 5-22.
22. Hannah-Shmouni, F., W. Chen, and D.P. Merke, *Genetics of Congenital Adrenal Hyperplasia*. Endocrinol Metab Clin North Am, 2017. **46**(2): p. 435-458.
23. Helmborg, A., et al., *R339H and P453S: CYP21 mutations associated with nonclassic steroid 21-hydroxylase deficiency that are not apparent gene conversions*. Mol Endocrinol, 1992. **6**(8): p. 1318-22.
24. Krone, N. and W. Arlt, *Genetics of congenital adrenal hyperplasia*. Best Pract Res Clin Endocrinol Metab, 2009. **23**(2): p. 181-92.
25. Haider, S., et al., *Structure-phenotype correlations of human CYP21A2 mutations in congenital adrenal hyperplasia*. Proc Natl Acad Sci U S A, 2013. **110**(7): p. 2605-10.
26. Al-Obaidi, R.G., et al., *Molecular Analysis of CYP21A2 Gene Mutations among Iraqi Patients with Congenital Adrenal Hyperplasia*. Enzyme Res, 2016. **2016**: p. 9040616.
27. R Core Team. *R: A language and environment for statistical computing*. R Foundation for Statistical Computing. 2022; Available from: <https://www.R-project.org/>.
28. Therneau, T. *A Package for Survival Analysis in R*. R package version 3.4-0. 2022; Available from: <https://CRAN.R-project.org/package=survival>.
29. Kassambara, A., M. Kosinski, and P. Biecek. *survminer: Drawing Survival Curves using 'ggplot2'*. R package version 0.4.9. 2021; Available from: <https://CRAN.R-project.org/package=survminer>.
30. Bas, F., et al., *CYP21A2 gene mutations in congenital adrenal hyperplasia: genotype-phenotype correlation in Turkish children*. J Clin Res Pediatr Endocrinol, 2009. **1**(3): p. 116-28.
31. Brunton (ed), L.L. and B.C. Knollmann (ed), *Goodman & Gilman's The Pharmacological Basis of Therapeutics, Fourteenth Edition*. 2022: McGraw Hill LLC.
32. Mosteller, R.D., *Simplified Calculation of Body-Surface Area*. New England Journal of Medicine, 1987. **317**(17): p. 1098-1098.
33. Sivit, C.J., et al., *Sonography in neonatal congenital adrenal hyperplasia*. AJR Am J Roentgenol, 1991. **156**(1): p. 141-3.
34. Scott, E.M., et al., *Serial adrenal ultrasonography in normal neonates*. J Ultrasound Med, 1990. **9**(5): p. 279-83.
35. Falhammar, H., et al., *Reduced Frequency of Biological and Increased Frequency of Adopted Children in Males With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study*. J Clin Endocrinol Metab, 2017. **102**(11): p. 4191-4199.
36. Tresoldi, A.S., et al., *Bilateral testicular masses and adrenal insufficiency: is congenital adrenal hyperplasia the only possible diagnosis? First two cases of TARTS described in Addison-only X-linked adrenoleukodystrophy and a brief review of literature*. J Endocrinol Invest, 2021. **44**(3): p. 391-402.
37. Ashley, R.A., et al., *Clinical and pathological features associated with the testicular tumor of the adrenogenital syndrome*. J Urol, 2007. **177**(2): p. 546-9; discussion 549.
38. Hamwi, G.J., et al., *Activation of Testicular Adrenal Rest Tissue by Prolonged Excessive Acth Production*. J Clin Endocrinol Metab, 1963. **23**: p. 861-9.
39. Puar, T., et al., *Bilateral Testicular Tumors Resulting in Recurrent Cushing Disease After Bilateral Adrenalectomy*. J Clin Endocrinol Metab, 2017. **102**(2): p. 339-344.
40. Krieger, D.T., E. Samojlik, and C.W. Bardin, *Cortisol and androgen secretion in a case of Nelson's syndrome with paratesticular tumors: response to cyproheptadine therapy*. J Clin Endocrinol Metab, 1978. **47**(4): p. 837-44.
41. Mendes-Dos-Santos, C.T., et al., *Prevalence of Testicular Adrenal Rest Tumor and Factors Associated with Its Development in Congenital Adrenal Hyperplasia*. Horm Res Paediatr, 2018. **90**(3): p. 161-168.

42. Yu, M.K., et al., *Clinical manifestations of testicular adrenal rest tumor in males with congenital adrenal hyperplasia*. Ann Pediatr Endocrinol Metab, 2015. **20**(3): p. 155-61.
43. Finkelstein, G.P., et al., *Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia*. J Clin Endocrinol Metab, 2012. **97**(12): p. 4429-38.
44. Adriaansen, B.P.H., et al., *Challenges in treatment of patients with non-classic congenital adrenal hyperplasia*. Front Endocrinol (Lausanne), 2022. **13**: p. 1064024.
45. Falhammar, H., et al., *Fertility, sexuality and testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia*. Eur J Endocrinol, 2012. **166**(3): p. 441-9.
46. Kocova, M., V. Janevska, and V. Anastasovska, *Testicular adrenal rest tumors in boys with 21-hydroxylase deficiency, timely diagnosis and follow-up*. Endocr Connect, 2018. **7**(4): p. 544-552.
47. Corcioni, B., et al., *Prevalence and ultrasound patterns of testicular adrenal rest tumors in adults with congenital adrenal hyperplasia*. Transl Androl Urol, 2021. **10**(2): p. 562-573.
48. Turcu, A.F., et al., *11-Oxygenated Androgens Are Biomarkers of Adrenal Volume and Testicular Adrenal Rest Tumors in 21-Hydroxylase Deficiency*. J Clin Endocrinol Metab, 2017. **102**(8): p. 2701-2710.
49. Shanklin, D.R., A.P. Richardson, Jr., and G. Rothstein, *Testicular Hilar Nodules in Adrenogenital Syndrome. The Nature of the Nodules*. Am J Dis Child, 1963. **106**: p. 243-50.
50. Bouman, A., C. Hulsbergen-van de Kaa, and H.L. Claahsen-van der Grinten, *Prevalence of testicular adrenal rest tissue in neonates*. Horm Res Paediatr, 2011. **75**(2): p. 90-3.
51. Reisch, N., et al., *High prevalence of reduced fecundity in men with congenital adrenal hyperplasia*. J Clin Endocrinol Metab, 2009. **94**(5): p. 1665-70.
52. Engels, M., et al., *Gonadal function in adult male patients with congenital adrenal hyperplasia*. Eur J Endocrinol, 2018. **178**(3): p. 285-294.
53. Kim, M.S., et al., *Testicular Adrenal Rest Tumors in Boys and Young Adults with Congenital Adrenal Hyperplasia*. J Urol, 2017. **197**(3 Pt 2): p. 931-936.
54. Bachelot, A., et al., *Determining clinical and biological indicators for health outcomes in adult patients with childhood onset of congenital adrenal hyperplasia*. Eur J Endocrinol, 2015. **173**(2): p. 175-84.
55. Delfino, M., et al., *Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia: prevalence and sonographic, hormonal, and seminal characteristics*. J Ultrasound Med, 2012. **31**(3): p. 383-8.
56. Claahsen-van der Grinten, H.L., et al., *Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency*. Eur J Endocrinol, 2007. **157**(3): p. 339-44.
57. Stikkelbroeck, N.M., et al., *High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia*. J Clin Endocrinol Metab, 2001. **86**(12): p. 5721-8.
58. Bonfig, W. and H.P. Schwarz, *Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life*. Horm Res Paediatr, 2011. **75**(4): p. 264-8.
59. Claahsen-van der Grinten, H.L., et al., *Absence of increased height velocity in the first year of life in untreated children with simple virilizing congenital adrenal hyperplasia*. J Clin Endocrinol Metab, 2006. **91**(4): p. 1205-9.

## 488 Figure and table legends

489 **Table 1:** General characteristics of study cohort, grouped by the presence and absence of TART. Percentages  
490 are calculated relative to all patients with CAH or, if specified, patients with 21OHD.

491 **Table 2:** Putative risk factors for TART diagnosis expressed as hazard ratio (HR) with 95% confidence intervals  
492 (CI). The assumption of proportional hazards was tested using Schoenfield's test.

493 **Figure 1:** Predicted non-occurrence probability of TART in men with 21OHD or 11OHD stratified by CAH  
494 phenotype (A) or grouped age at CAH diagnosis (B) and the effect of neonatal screening on age at 21OHD  
495 diagnosis (C) and occurrence of adrenal crisis at 21OHD diagnosis (D).

496 **Figure 2:** Retrospective height for age SDS corrected for target height SDS (A) and bone age versus  
497 chronological age (B) of assessments during the first four years of life in patients with and without TART  
498 diagnosis in their lifetime.

499

500 Table 1

		Overall	TART	No TART
n		188	72	116
	21OHD	181 (96%)	68 (94%)	113 (97%)
	11OHD	7 (3.7%)	4 (5.6%)	3 (2.6%)
<b>Presumed 21OHD type (n=181)</b>				
	SW	103 (57%)	40 (59%)	63 (56%)
	SV	29 (16%)	4 (5.9%)	25 (22%)
	SV/NC	6 (3.3%)	3 (4.4%)	3 (2.7%)
	NC	14 (7.7%)	2 (2.9%)	12 (11%)
	Unknown	29 (16%)	19 (28%)	10 (8.8%)
<b>Age at last US</b>		13 (10-17)	15 (11-18)	12 (10-16)
<b>Neonatal screening (21OHD)</b>				
	Yes	58 (32%)	9 (13%)	49 (43%)
	No	102 (56%)	52 (77%)	50 (44%)
	Not known	21 (12%)	7 (10%)	14 (12%)
<b>Adrenal/salt-wasting crisis at diagnosis</b>				
	Yes	67 (36%)	35 (49%)	32 (28%)
	No	93 (50%)	26 (36%)	67 (58%)
	Not known	28 (15%)	11 (15%)	17 (15%)
<b>Age at diagnosis</b>				
	<1 month	92 (49%)	24 (33%)	68 (59%)
	> 1 month and <1 year	38 (20%)	23 (32%)	15 (13%)
	≥1 year	51 (27%)	20 (28%)	31 (27%)
	Not known	7 (3.7%)	5 (6.9%)	2 (1.7%)

501

502

503

504 Table 2

		Schoenfield's p	Events	HR	CI	p-value
<b>CAH type</b>						
	SW vs SV	0.867	72/188	3.250	1.158-9.121	<b>0.03</b>
	SV/NC vs SV			8.457	1.857-38.522	<b>&lt;0.01</b>
	NC vs SV			2.603	0.467-14.519	0.28
	Not known vs SV			3.604	1.236-10.507	<b>0.02</b>
<b>Age diagnosis grouped*</b>						
	< 1 year > 1 month vs < 1 month	0.993	72/188	1.438	0.784-2.639	0.24
	> 1 year vs < 1 month			2.645	1.374-5.091	<b>&lt;0.01</b>
	Not known vs < 1 month			0.945	0.318-2.806	0.92
<b>Neonatal screening*</b>						
	No vs Yes	0.057	72/188	3.242	1.551-6.779	<b>&lt;0.01</b>
	Not known vs Yes			1.098	0.382-3.156	0.863
<b>Biochemical control visit 2 (year 1)*</b>						
	Overtreatment vs Adequate	0.288		0.717	0.228-2.252	0.57
	Undertreatment vs Adequate			0.863	0.214-3.479	0.84
	Not known vs Adequate			0.873	0.363-2.097	0.76
<b>Biochemical control visit 3 (year 2)*</b>						
	Overtreatment vs Adequate	0.562		0.957	0.269-3.409	0.95
	Undertreatment vs Adequate			1.842	0.590-5.750	0.29
	Not known vs Adequate			1.288	0.532-3.122	0.58
<b>Biochemical control visit 4 (year 3)*</b>						
	Overtreatment vs Adequate	0.186		0.664	0.193-2.279	0.52
	Undertreatment vs Adequate			2.161	0.720-6.488	0.17
	Not known vs Adequate			0.970	0.427-2.204	0.94
<b>Biochemical control visit 5 (year 4)*</b>						
	Overtreatment vs Adequate	0.187		0.626	0.188-2.087	0.45
	Undertreatment vs Adequate			1.413	0.449-4.450	0.56
	Not known vs Adequate			1.001	0.478-2.096	1.00


<b>Corrected height SDS visit 5</b>	0.062	37/98	1.271	1.062-1.521	<b>&lt;0.01</b>
<b>Bone age advancement (years) visit 5</b>	0.080	21/58	1.115	0.927-1.341	0.25

*\*Adjusted for CAH type*

505

506


507 Figure 1



508

509

510 Figure 2



511